TDAC
TDAC
Translational Development Acquisition Corp.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $137.68K ▼ | $4.28M ▲ | $1.66M ▲ | 1.21K% ▲ | $0.08 ▲ | $-213.66K ▲ |
| Q2-2025 | $191.76K ▼ | $221.13K ▼ | $1.62M ▲ | 846.54% ▲ | $0.07 ▼ | $-221.13K ▲ |
| Q1-2025 | $223.85K ▲ | $347.41K ▲ | $1.48M ▲ | 662.53% ▲ | $0.37 ▲ | $-347.41K ▼ |
| Q4-2024 | $0 | $133.39K ▲ | $-8.04K ▲ | 0% | $-0 ▲ | $-135.07K ▼ |
| Q3-2024 | $0 | $61.28K | $-61.28K | 0% | $-0.02 | $-61.28K |
What's going well?
Net income and EPS are up slightly, and there is no interest or tax burden this quarter. The company is still posting a profit on paper.
What's concerning?
Revenue dropped sharply, costs are out of control, and the core business is losing money. Profits are only coming from unusual, non-operating items, not from selling products or services.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $47.15K ▲ | $179.98M ▲ | $6.46M ▲ | $173.52M ▲ |
| Q2-2025 | $35.26K ▼ | $178.18M ▲ | $6.32M ▼ | $171.86M ▲ |
| Q1-2025 | $206.6K ▼ | $176.6M ▲ | $6.36M ▲ | $170.24M ▲ |
| Q4-2024 | $438.17K ▲ | $175M ▲ | $6.25M ▲ | $168.75M ▲ |
| Q3-2024 | $224.04K | $393.77K | $964.4K | $-570.63K |
What's financially strong about this company?
The company has almost no debt and a very large equity cushion. Most of its assets are long-term investments, and it paid down nearly all its debt this quarter.
What are the financial risks or weaknesses?
Cash on hand is extremely low compared to bills due soon, and current assets can't cover current liabilities. The company also has negative retained earnings and rising intangible assets, which could be risky if those values are overstated.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.66M ▲ | $-1.24M ▼ | $-2.1M ▼ | $8.58M ▲ | $11.89K ▲ | $-1.24M ▼ |
| Q2-2025 | $1.62M ▲ | $-171.34K ▼ | $0 ▲ | $0 ▼ | $-171.34K ▼ | $-171.34K ▲ |
| Q1-2025 | $1.48M ▲ | $924.9K ▲ | $-1.25M ▲ | $697.02K ▼ | $400.64K ▲ | $-231.57K ▲ |
| Q4-2024 | $-8.04K ▲ | $-810.96K ▼ | $-174.22M ▼ | $175.25M ▲ | $214.14K ▲ | $-810.96K ▼ |
| Q3-2024 | $-61.28K | $-40.48K | $0 | $192.5K | $152.02K | $-40.48K |
What's strong about this company's cash flow?
The company can still access outside funding and is returning cash to shareholders through dividends. Working capital changes provided a small temporary cash boost.
What are the cash flow concerns?
Cash burn is rising fast, and dividends are being paid with borrowed money, not profits. The company has almost no cash left and is highly dependent on new financing.
5-Year Trend Analysis
A comprehensive look at Translational Development Acquisition Corp.'s financial evolution and strategic trajectory over the past five years.
TDAC has transitioned from a small, loss-making shell into a large, revenue-generating entity on paper, with strong gross margins and a much healthier equity and liquidity profile. The sponsor team brings sector and financial expertise, and the company has demonstrated an ability to raise substantial capital and execute a transformative transaction. Short-term solvency appears comfortable, giving management some breathing room to refine operations and integrate the acquired business.
Key risks center on quality and sustainability. The balance sheet is dominated by goodwill and other intangibles, leaving it exposed to future write-downs if performance disappoints. Cash flows from operations and free cash flow are deeply negative, indicating that the business is not yet self-funding and remains dependent on external capital. Reported debt levels are very large and financing structures complex. On top of this, limited transparency about the underlying operating business makes it difficult to assess competitive dynamics, regulatory exposure, and true economic strength.
The outlook is highly transitional and uncertain. If the acquired business can validate the strong gross margins with consistent cash generation, demonstrate a defensible position in its end markets, and gradually reduce reliance on external financing, TDAC’s financial profile could improve significantly over time. Conversely, if revenue proves less durable than it appears, cash burn continues, or the intangibles on the balance sheet prove overly optimistic, the company could face pressure on both earnings and equity. Future disclosures about the target business, its strategy, and its cash generation will largely determine how the story develops from here.
About Translational Development Acquisition Corp.
https://www.translational-development.co...Translational Development Acquisition Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $137.68K ▼ | $4.28M ▲ | $1.66M ▲ | 1.21K% ▲ | $0.08 ▲ | $-213.66K ▲ |
| Q2-2025 | $191.76K ▼ | $221.13K ▼ | $1.62M ▲ | 846.54% ▲ | $0.07 ▼ | $-221.13K ▲ |
| Q1-2025 | $223.85K ▲ | $347.41K ▲ | $1.48M ▲ | 662.53% ▲ | $0.37 ▲ | $-347.41K ▼ |
| Q4-2024 | $0 | $133.39K ▲ | $-8.04K ▲ | 0% | $-0 ▲ | $-135.07K ▼ |
| Q3-2024 | $0 | $61.28K | $-61.28K | 0% | $-0.02 | $-61.28K |
What's going well?
Net income and EPS are up slightly, and there is no interest or tax burden this quarter. The company is still posting a profit on paper.
What's concerning?
Revenue dropped sharply, costs are out of control, and the core business is losing money. Profits are only coming from unusual, non-operating items, not from selling products or services.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $47.15K ▲ | $179.98M ▲ | $6.46M ▲ | $173.52M ▲ |
| Q2-2025 | $35.26K ▼ | $178.18M ▲ | $6.32M ▼ | $171.86M ▲ |
| Q1-2025 | $206.6K ▼ | $176.6M ▲ | $6.36M ▲ | $170.24M ▲ |
| Q4-2024 | $438.17K ▲ | $175M ▲ | $6.25M ▲ | $168.75M ▲ |
| Q3-2024 | $224.04K | $393.77K | $964.4K | $-570.63K |
What's financially strong about this company?
The company has almost no debt and a very large equity cushion. Most of its assets are long-term investments, and it paid down nearly all its debt this quarter.
What are the financial risks or weaknesses?
Cash on hand is extremely low compared to bills due soon, and current assets can't cover current liabilities. The company also has negative retained earnings and rising intangible assets, which could be risky if those values are overstated.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.66M ▲ | $-1.24M ▼ | $-2.1M ▼ | $8.58M ▲ | $11.89K ▲ | $-1.24M ▼ |
| Q2-2025 | $1.62M ▲ | $-171.34K ▼ | $0 ▲ | $0 ▼ | $-171.34K ▼ | $-171.34K ▲ |
| Q1-2025 | $1.48M ▲ | $924.9K ▲ | $-1.25M ▲ | $697.02K ▼ | $400.64K ▲ | $-231.57K ▲ |
| Q4-2024 | $-8.04K ▲ | $-810.96K ▼ | $-174.22M ▼ | $175.25M ▲ | $214.14K ▲ | $-810.96K ▼ |
| Q3-2024 | $-61.28K | $-40.48K | $0 | $192.5K | $152.02K | $-40.48K |
What's strong about this company's cash flow?
The company can still access outside funding and is returning cash to shareholders through dividends. Working capital changes provided a small temporary cash boost.
What are the cash flow concerns?
Cash burn is rising fast, and dividends are being paid with borrowed money, not profits. The company has almost no cash left and is highly dependent on new financing.
5-Year Trend Analysis
A comprehensive look at Translational Development Acquisition Corp.'s financial evolution and strategic trajectory over the past five years.
TDAC has transitioned from a small, loss-making shell into a large, revenue-generating entity on paper, with strong gross margins and a much healthier equity and liquidity profile. The sponsor team brings sector and financial expertise, and the company has demonstrated an ability to raise substantial capital and execute a transformative transaction. Short-term solvency appears comfortable, giving management some breathing room to refine operations and integrate the acquired business.
Key risks center on quality and sustainability. The balance sheet is dominated by goodwill and other intangibles, leaving it exposed to future write-downs if performance disappoints. Cash flows from operations and free cash flow are deeply negative, indicating that the business is not yet self-funding and remains dependent on external capital. Reported debt levels are very large and financing structures complex. On top of this, limited transparency about the underlying operating business makes it difficult to assess competitive dynamics, regulatory exposure, and true economic strength.
The outlook is highly transitional and uncertain. If the acquired business can validate the strong gross margins with consistent cash generation, demonstrate a defensible position in its end markets, and gradually reduce reliance on external financing, TDAC’s financial profile could improve significantly over time. Conversely, if revenue proves less durable than it appears, cash burn continues, or the intangibles on the balance sheet prove overly optimistic, the company could face pressure on both earnings and equity. Future disclosures about the target business, its strategy, and its cash generation will largely determine how the story develops from here.

CEO
Michael M. B. Hoffman
Compensation Summary
(Year 2023)
Ratings Snapshot
Rating : B+
Price Target
Institutional Ownership
WOLVERINE ASSET MANAGEMENT LLC
Shares:1.56M
Value:$16.41M
MAGNETAR FINANCIAL LLC
Shares:1.3M
Value:$13.7M
AQR ARBITRAGE LLC
Shares:1.1M
Value:$11.56M
Summary
Showing Top 3 of 47

